Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck has agreed to acquire US-based clinical-stage biopharmaceutical company VelosBio for $2.75bn in cash.
Merck has agreed to acquire clinical-stage biopharmaceutical company VelosBio. (Credit: Tumisu from Pixabay)
Subscribe to our email newsletter
Based in San Diego, VelosBio is involved in the development of first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1).
VLS-101, the company’s investigational antibody-drug conjugate (ADC) targeting ROR1, is currently being assessed in a phase I and a phase 2 clinical study to treat patients with haematologic malignancies and solid tumours.
VelosBio is using its ROR1-targeting antibody-based technology for the development of a pipeline of ADCs and bispecific antibody product candidates to treat haematologic malignancies and solid tumours.
VelosBio founder and CEO Dave Johnson said: “We are very pleased that Merck has recognized the value of our first-in-class ROR1-directed investigational therapeutics.
“As part of Merck’s oncology pipeline, our lead product candidate, VLS-101, is now well-positioned to achieve its maximum potential to benefit appropriate cancer patients in need.”
In October this year, VelosBio commenced phase 2 clinical study to assess VLS-101 to treat patients with solid tumours, including patients with triple-negative breast cancer (TNBC), hormone receptor-positive and/or HER2-positive breast cancer, and non-squamous non-small-cell lung cancer (NSCLC).
According to the company, VLS-101 showed a manageable safety profile and early signs of anti-tumour activity in early clinical trials.
Subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, the deal is expected to be completed by the end of this month.
Merck Research Laboratories president Dr Roger Perlmutter said: “Pioneering work by VelosBio scientists has yielded VLS-101, which in early studies has provided notable evidence of activity in heavily pretreated patients with refractory hematological malignancies, including mantel cell lymphoma and diffuse large B-cell lymphoma.”
Gibson Dunn & Crutcher acted as legal advisor and J.P. Morgan Securities served as a financial advisor for Merck for the transaction. Cooley served as legal advisor and Centerview Partners acted as a financial advisor for VelosBio.
In September, Merck announced the acquisition of a $1bn equity stake in biotechnology company Seattle Genetics.
Merck and Seattle Genetics have entered into two strategic oncology collaborations to commercialise Seattle Genetics’ antibody-drug conjugate (ADC) ladiratuzumab vedotin and small-molecule tyrosine kinase inhibitor (TKI) Tukysa (tucatinib).
